UCB drops Parkinson’s treatment after ORCHESTRA trial failed all endpoints
The Phase II trial ended meeting none of its endpoints as the company announces plans to pivot away from the drug in favour of others.
18 December 2024
18 December 2024
The Phase II trial ended meeting none of its endpoints as the company announces plans to pivot away from the drug in favour of others.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.